



IMUGENE

Animal Health Biological Products

2006 Annual Review – Highlights & Update

November 2006

Dr Warwick Lamb

Managing Director





IMUGENE

Product & Industry Focus

- **Biological animal health products**
- **Proven & patented platform science**
- **Advanced products with market demand & need**
- **Strong product pipeline**
- **Early licensing success**
- **Early regulatory approvals**

The top banner features a blue background. On the left, there is a blurred image of laboratory glassware, including beakers and test tubes. On the right, there is a blurred image of a brown chicken. The text is centered in white with a slight drop shadow.

Highlights

Poultry Productivity Enhancer

- **Licensed to Merial in Oct 2005**
- **Completion of two Australian safety trials**
- **Sign-up fees received & milestone payment recently earned**
- **Progressing through product development for global and Australian commercial releases**

The top banner of the slide features a blue background. On the left, there is a blurred image of laboratory glassware, including several Erlenmeyer flasks and beakers. On the right, there is a blurred image of a brown chicken. The title 'Highlights Avian Influenza' is centered in white text with a slight drop shadow.

Highlights Avian Influenza

- **Two vaccine candidates completed**
 - **For broilers & layers/breeders**
- **Fully lab tested**
- **High quality trial site secured in US**
- **Poultry trials to commence this quarter**
- **Successful grant funding of \$882,000 for product development**
- **International interest**

The top banner features a blue background. On the left, there is a blurred image of laboratory glassware, including beakers and test tubes. On the right, there is a blurred image of a chicken. The text 'Highlights Coccidiosis' is centered in white with a slight drop shadow.

Highlights Coccidiosis

- **Vaccine candidates completed**
- **Final candidate verification underway**
- **Expect to handover to Teva/Abic for poultry trials in early 2007**
- **Anticipate licensing FAV for delivery of these vaccines if successful in trials**



Highlights Patents

- **Successfully defended US interference proceedings for PAV**
- **Improved patent position in US with patent assignment**
- **Lodged new patent for PAV in US**
 - **Prolonged commercial protection**
- **FAV patent granted in Europe**



Highlights Imugene Laboratory

- **Successfully established our own leasehold laboratory facility at La Trobe University**
- **Significant improvement in scientific progress – both quality and timeframes**
- **Focused commercial research**
- **Marked improvement in product quality control**

The top banner features a blue background. On the left, there is a blurred image of laboratory glassware, including beakers and test tubes. On the right, there is a blurred image of a green chicken. The text 'Highlights Regulatory' is centered in white with a drop shadow.

Highlights Regulatory

- **New Imugene Institutional Biosafety Committee**
- **Applications lodged for OGTR licences for PAV and FAV laboratory work**
- **Intentional Release application for the Poultry Productivity Enhancer for final submission to OGTR**



Update Pig Vaccines

- **PAV-PRRS US trial site**
 - Final negotiation phase
- **PAV-Merial product improvements**
- **PAV pipeline – product dependent pathways**



Activity

1ST Half 2007

- **Expanding Imugene's animal health reputation in US and Europe**
- **Further US based product trials**
- **Advancing international commercial arrangements**

The background of the slide features a blue gradient. On the left, there is a faint image of laboratory glassware, including beakers and test tubes. On the right, there is a faint image of a brown chicken.

Activity – Poultry

1ST Half 2007

- **Avian flu trial**
 - To be completed Jan 2007
 - Interim results – Jan 2007
 - Full results – first quarter 2007
- **Poultry Productivity Enhancer**
 - Regulatory progress – OGTR
 - Product development funded by Merial
- **Coccidiosis**
 - Vaccine constructs to be trialled by Teva / Abic

The background of the slide features a blue gradient. On the left, there is a blurred image of laboratory glassware, including beakers and test tubes. On the right, there is a blurred image of a pig's head.

Activity – Pigs

1ST Half 2007

- **Pig vaccines**
 - US based PRRS vaccine trial
 - Improved PAV-Merial vaccines constructed and delivered to Merial
 - Other PAV products developed for disease specific markets
- **PAV patents**
 - International prosecution of new PAV patent



Update Financial Position

- **Net cash outflow – \$137k/mth = under budget**
- **2007 budget approx \$150k/mth**
- **Merial funding development work on Poultry Productivity Enhancer**
- **\$2.3m cash – Sep 06**
- **\$880k Government grant for Bird Flu – 2 years**
- **Financial returns from Merial licence**
- **Contract payments due from Teva/Abic**
- **Teva/Abic to fund trials & product development**

Update Corporate

- **Directors & management**
 - Graham Dowland – Chairman
 - Warwick Lamb – CEO
 - Roger Steinepreis – Director
 - Mike Sheppard – Chief Scientific Officer

- **Shares on issue** **130 m**
(QIC – 5.7%, Board – 13%)

- **Options on issue**
 - Expiry 31 Dec 06 (25c-30c) **6.2 m**
 - Expiry 31 Jan 07 (50c) **4.5 m**
 - Expiry 31 Oct 07 (22.5c-37.5c) **4.9 m**